anti-IFN-beta BAB ELISA

For an Efficient Patient and Cost Management

Antibody induced Reduction of IFN-beta Efficacy?

The only commercial ELISA assay for anti-IFN-beta antibody screening

Best correlation with overall NAB titers

Simple and reliable test procedure

Supports cost efficient therapy management for Multiple Sclerosis
Monitoring the Efficacy of IFN-beta Therapies

IFN-beta in Multiple Sclerosis, an Overview

Multiple Sclerosis (MS) affects over 2.5 mio individuals worldwide and is the most common disease of the CNS that causes prolonged and severe disability. IFN-beta is the most commonly used treatment in Relapsing/Remitting Multiple Sclerosis (RRMS). The widely used disease modifying agents with annual global sales of $3 billion are Interferon-beta 1a and -1b. Various studies have proven the value of these biologicals in the treatment of RRMS by reducing the relapse rates by 30% and increasing the remittance time span. These therapies are very expensive (15 - 17 k€ per year/patient).

IFN-beta Antibodies

Caused by the appearance of anti IFN-beta Antibodies, a substantial number of patients fail to respond to IFN-beta therapies. Antibody mediated decrease in bioactivity, will lead to decreased clinical effect of injected IFN-beta.

<table>
<thead>
<tr>
<th>Commercial name</th>
<th>Betaferon®</th>
<th>Betaseron®</th>
<th>Rebif®</th>
<th>Avonex®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell origin</td>
<td>E. coli</td>
<td>mammalian</td>
<td>mammalian</td>
<td>mammalian</td>
</tr>
<tr>
<td>IFN-beta</td>
<td>1b</td>
<td>IFN-beta 1a</td>
<td>IFN-beta 1a</td>
<td>IFN-beta 1a</td>
</tr>
<tr>
<td>Market share [in Mio US$]</td>
<td>1200</td>
<td>1375</td>
<td>1000</td>
<td></td>
</tr>
<tr>
<td>Immunogenicity of IFN-beta Therapies</td>
<td>45%</td>
<td>24%</td>
<td>5%</td>
<td></td>
</tr>
</tbody>
</table>

Binding Antibodies (BABs) to IFN-beta develop as early as 3 months during therapy in up to 80% of treated patients and Neutralizing antibodies (NABs) prevent the binding of the Interferon to its receptor on the target cells, neutralizing the biological effects of IFN-beta.

NABs have clearly been shown to be a subset of BABs.

Should routine screens for anti-IFN-beta antibodies be performed?

It is highly important to control the antibody status early on during therapy as BABs/NABs appear after 3 - 6 months and are highly predictive indicators for therapy success, as the clinical effects of NABs only appear around 18 months after therapy starts!

The Bühlmann BAB Assay is suggested as first step screening tool. It is simple, quick and inexpensive!

In a second step NAB Assays can be performed with the positive samples from the previous BAB screening. NAB tests are activity assays. They are time consuming and more difficult to perform.

Generally, only samples that are positive for BAB are assayed for NABs.

The Guidelines of the EFNS (European Federation of Neurological Societies) on IFN-beta Antibodies are very clear:

BAB assays: BAB assays can be reliably used for IFN-beta antibody screening before performing a NAB assay (level A recommendation)

BAB & NAB assays: measurements of BABs and NABs against IFN-beta should be performed in specialized laboratories (level A recommendation).

Tests for the presence of NABs should be performed at 12 and 24 months of therapy (level A recommendation).

Therapy with IFN-beta should be discontinued in patients with high titers of NABs sustained at repeated measurements with 3 – 6 month intervals (level A recommendation).

The anti-IFN-beta ELISA from BÜHLMANN fits these requirements completely.

● a simple ELISA assay yielding results in 4.5 hours.
● Can be run semi-automated.
● Cheap compared to any NAB test and other BAB products.
● CE-marked, intra- and inter-laboratory correspondance.

A recent study by an IFN-beta expert group acknowledged the BÜHLMANN BAB ELISA to be a valuable tool for the IFN-beta antibody screening test:

In comparison with other methods, the EIA (BÜHLMANN BAB Assay) had the best overall correlation to NAB titers (from Gneiss et al, ECTRIMS 2005).

Literature
Hesse, D and Sørensen, PS Using measurements of neutralizing antibodies: the challenge on IFN-beta therapy; Europ J Neurol, 14(8), 850-9 (2007)

BÜHLMANN Laboratories AG
Baselstrasse 55
CH-4124 Schönenbuch/Basel
Switzerland

Phone +41 61 487 12 12
Fax orders +41 61 487 12 99
info@buhlmannlabs.ch
www.buhlmannlabs.ch

Ordering code: EK-IFNB 96 wells

BETASERON® (Betaferon®) is a registered trademark of Merck Serono
AVONEX® is a registered trademark of Biogen Idec

BETAFERON® (Betaseron®) is a registered trademark of Bayer Schering

The Bühlmann BAB Assay is suggested as first step screening tool. It is simple, quick and inexpensive!